strong fundament catalyst
initi coverag idorsia neutral rate tp idorsia
clinical-stag biotech compani specialis develop small
molecul pre-commerci biotech compani idorsia unusu
cash experienc team state-of-the-art facil
day one led strong manag team proven track record
although idorsia four phase asset believ offer neutral
risk/reward profil three reason phase asset
blockbust potenti aprocitentan out-licens johnson johnson
analys collabor us pharma team cse peak sale
po novel dual endothelin receptor antagonist
treatment resist hypertens dora cse peak po
novel dual orexin receptor antagonist dora treatment
insomnia unmet need indic lead strong demand
support fact fda-approv dora suvorex market
merck cover us pharma team cse peak seen
grow sale insomnia without ideal pharmacolog profil quiet
despit idorsia rich pipelin relev studi produc result
howev expect multipl catalyst high
expens despit gross cash balanc sheet expect
idorsia reach break-even annual cash burn
assum idorsia need rais addit capit idorsia
alreadi convert bond loan outstand addit capit
rais would translat combin dilut estim
catalyst risk ponesimod royalti idia phase data
biotech-specif risk relat clinic develop product take-up
idorsia use proprietari pharmavalu
methodolog risk-adjust discount cash flow explicit forecast
period appli discount rate account higher risk
profil early-stag biotech compani lead target price
valuat metric
number share
price month
price rel chart measur perform
swiss market ind close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
idorsia biotechnolog compani focus therapeut agent
interact protein-coupl receptor idorsia demerg
actelion experienc employe state-of-
the-art facil prosper pipelin chf cash
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
scenario assum po aprocitentan
dora clazosentan lucerastat cenerimod
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
grey scenario assum lower sale
aprocitentan dora clazosentan lucerastat non-approv
cenerimod
price rel chart measur perform swiss market
ind close
spot exchang rate
figur timelin cs forecast
figur pipelin key catalyst
usd
vasospasm associ aneurysm
vasospasm associ aneurysm
figur net gross cash oper profit
idorsia capit rais
credit suiss estim share price april
charl martineau univers toronto tabl content
aprocitentan endothelin receptor antagonist novel mechan action
dora dual orexin receptor antagonist new gener drug treat insomnia
aneurysm subarachnoid haemorrhag
initi coverag idorsia clinical-stag biotech compani list swiss
exchang neutral rate target price
idorsia found actelion earli stage pipelin demerg
time jnj acquisit actelion former actelion employe continu
work state-of-the-art facil exist project idorsia fund
cash day one actelion manag notabl jean-paul
martin clozel largest idorsia sharehold combin stake remain
charg smooth demerg process ensur continu stabil
reflect valu place experi idorsia key peopl research
develop commun regul commercialis ad
probabl success ascrib idorsia late-stag drug
idorsia specialis develop small molecul particularli g-protein coupl
receptor agonists/antagonist resist hypertens aprocitentan insomnia dora
vasospasm clazosentan fabri diseas lucerastat system lupu erythematosu
compani collabor compound aprocitentan manag
said intend commercialis rare diseas asset therefor assum
idorsia enter collabor agreement dora cenerimod
develop commercialis clazosentan lucerastat long term idorsia
founder aim build sustain commerci organis combin sale potenti
forecast
figur timelin cs forecast idorsia product
usd
howev despit blockbust candid aprocitentan dora idorsia face quiet
catalyst emerg larg expens clinic studi
therefor believ compani neutral risk/reward profil
aprocitentan dora potenti blockbust
idorsia two-lat stage drug candid pipelin believ blockbust
aprocitentan novel dual eta etb endothelin receptor antagonist treat
dora new-gener drug treat insomnia
aprocitentan cse world-wide peak po npv
hypertens major risk heart diseas stroke two main caus death
world resist hypertens defin blood pressur remain level
defin hypertens despit concurr administr antihypertens
therapi maxim toler dose blood pressur requir therapi
adult us popul nearli million peopl suffer elev
blood pressur diagnos hypertens suffer
resist hypertens patient highest unmet medic need within
group true resist hypertens account resist
hypertens patient nearli million us citizen
present pharmacolog treatment avail resist hypertens
differ therapi treat hypertens addit rather
compos compound target complementari physiolog mechan
aprocitentan novel dual eta etb endothelin receptor antagonist
potenti reduc hypertens although mechan action new gener
new treatment hypertens phase studi demonstr
statist signific efficaci dose-depend manner favour aprocitentan
lisinopril placebo confirm effect high toler safeti
idorsia develop commercialis aprocitentan collabor take
lead conduct regist trial resist hypertens registr
cost split equal compani howev entitl phase
studi addit indic cost would still split provid idorsia
receiv royalti aprocitentan
model target popul us europ japan combin
assum yearli cost per patient us ex-
us assum world-wide peak penetr aprocitentan result
peak sale royalti idorsia owe high
unmet medic need statist signific clinic relev phase result
experienc manag team strong global partner assum probabl
success industri averag drug clinic stage
cover us pharma team collabor assumpt
includ model
aprocitentan npv idorsia total estim
scenario show aprocitentan approv po
contribut target price would increas per share els equal
convers grey scenario assum lower sale would lower
contribut target price per share
dora cse world-wide peak po npv total
insomnia common sleep disord world roughli gener
popul suffer sleep disrupt approxim associ symptom
daytim function impair accord nation institut nih
divers treatment possibl address insomnia includ medic treatment
main goal medic treatment improv speed sleep onset restor
natur sleep pattern avoid next-day hangov effect commonli prescrib
insomnia drug gaba agent characteris high addict rate
loss memori
howev even though gaba agent perfect insomnia drug prescript rate
increas earli reach peak prescript declin
associ american medic associ highlight gaba-
induc epidem threat similar opioid addict epidem addit danger
combin opioid gaba agent could lead respiratori depress
dizzi death highlight
potenti advantag dual orexin receptor antagonist dora mechan
action promot sleep shut brain like gaba agent
instead promot sleep affect wake system orexin system
promot arous block potenti promot sleep importantli
orexin system block arous system scientif commun believ
influenc sleep pattern could induc normal sleep minimis impact
memori next-day hangov effect dora block excitatori receptor
instead stimul inhibitori receptor gaba agent believ
potenti trigger addict
promis properti dora agent high unmet medic need new
effect non-addict treatment lead us assum dora agent take
market share gener agent market share latter declin
assumpt base data show increas absolut sale number
sinc launch suvorex brand name belsomra first far dora
market commercialis merck cover us pharma team cse peak sale
develop remark given suvorex ideal
insomnia drug profil see dora suggest superior pharmacolog profil
compar suvorex
eisai purdu pharma also develop dora lemborex see
competit threat suvorex lemborex addit studi
suggest superior pharmacolog profil suvorex lemborex
see lemborex step ahead furthermor compani alreadi file new
drug applic nda fda pdufa date decemb mean
could approv phase readout idorsia dora
howev see risk commercialis purdu
subject signific neg public relat role market opioid
oxycontin march purdu member sackler famili
compani agre pay settl lawsuit brought state oklahoma
reuter march accord press report reuter march
purdu consid file bankruptci given number lawsuit compani
face although purdu like right experi resourc promot
lemborex believ first need sort legal challeng eisai cover
japan pharma team forecast lemborex peak sale
said unmet need new insomnia drug high market
substanti believ space one success novel agent within
insomnia space furthermor lemborex could also educ market creat
favour condit entranc new dora agent idorsia dora
idorsia two phase trial on-going test proprietari dora phase data
promis expect phase data summer accord idorsia
manag addit studi prove lack addict also
way phase data confirm dora superior believ potenti
standard care insomnia boost manag team proven
commerci execut skill eg pah actelion
believ idorsia dora potenti reach world-wide peak sale
assum probabl success stage develop
industri averag owe proven mechan action dora high
unmet need substanti market experienc manag team
assum drug prescrib gener practition psychiatrist
idorsia therefor enter distribut agreement global oper howev
believ idorsia tri retain much valu possibl enter
agreement asset de-risk phase result time
believ idorsia could abl retain around profit
dora npv compani total estim
scenario suggest dora approv po
contribut target price would increas per share contrast grey
scenario assum lower sale reduc contribut target price
four substanti phase programm high opex catalyst
idorsia rich pipelin asset spread across clinic develop four asset
phase three asset phase three asset phase see figur
see blockbust potenti two phase asset name aprocitentan dora
despit number on-going programm expect catalyst idorsia
proprietari phase asset
figur idorsia pipelin key catalyst
clazosentan jp
vasospasm associ aneurysm
vasospasm associ aneurysm
conserv includ late-stag product aprocitentan dora clazosentan
lucerastat cenerimod ponesimod royalti idia vamorolon
reveragen/santhera licens reveragen sub-licens santhera model
therefor even though believ earli stage asset proceed smoothli
next clinic stage contribut idorsia valuat yet although
see lack catalyst short term expect spend clinic trial remain
high longer term
despit lucr deal consider amount gross cash balanc sheet
decemb expect compani break even
earliest annual cash burn rate estim
mileston appli estim phase asset sale market expens
align expens probabl success even assum idorsia make use
outstand credit facil cilag suggest need
addit capit least
idorsia alreadi convert bond convert share
convert loan convert share outstand addit would
translat addit dilut idorsia share current share count
although high spend might disturb averag biotech compani
concern regard idorsia given numer promis asset combin
experienc manag team compani financ year
first set catalyst catalyst posit could open access
differ fund option includ royalti bank credit fund
idorsia gener strategi enter therapeut area littl competit
case compani drug develop
consider competit within insomnia market highli genericis
gener insomnia drug reli old mechan action gaba account
market howev side effect gaba neglig
agent highli addict strong medic need new mechan action
treat insomnia addit sleep essenti human economi lose
substanti amount money result sleep depriv expect govern
support new innov insomnia treatment
dual orexin receptor antagonist dora agent new innov address
unmet medic need even though first far approv dora suvorex
trade name belsomra commercialis merck ideal insomnia profil
label approv narrow rang file sale price/
increas steadili sinc launch late total sale insomnia
drug decreas time period figur figur figur although
think suvorex seriou threat idorsia dora believ
pharmacolog profil compar suvorex see competit threat
emerg eisais/purdu dora lemborex compani present posit
phase result alreadi file nda insomnia disord treatment
lemborex fda pdufa date decemb see lemborex step ahead
data present demonstr convinc clinic evid suvorex
approv lemborex could enter market even present
idorsia dora phase data expect summer
superior
typic clinical-stag biotechnolog compani idorsia product market
yet expect earliest despit lucr deal
consider amount cash idorsia receiv incept expect compani
reach break-even earliest owe annual cash burn rate
impli idorsia need addit capit assum
addit far undrawn credit facil cilag idorsia
need rais capit amount evenli split
would equival compani current market cap togeth
compani exist outstand potenti dilut convert loan
convert share convert bond convert
share consid capit rais addit risk see burn
moreov dora meet mileston forecast
probabl capit requir even higher see figur
although reflect risk estim model probabl success po
think idorsia late-stag drug candid potenti approv
think challeng approv environ pose risk approv clazosentan ex-
jp see commerci potenti like japan attribut probabl
success model
consid earli stage pipelin risk reward report
view success idorsia depend strongli highli qualifi leadership team
although expect chang manag alway risk
find equival successor anyon leav
valu idorsia sum-of-the-part npv idorsia late-stag asset detail see
dcf valuat asset base credit suiss proprietari pharmavalu
platform pharmavalu well-establish methodolog identifi key long-
term valu driver compani provid product-by-product valuat facilit
detail scenario analys impact futur event outcom drug
compani valu explicitli highlight key input investor determin
sensit compani npv key variabl includ pipelin develop
mileston drug regulatori decis patent life scenario
within pharmavalu compani analys use standard life-cycle npv
algorithm provid consist valuat approach irrespect account
standard use early-stag biotech compani pharmavalu databas
use base-cas discount rate
forecast assum idorsia need draw credit line
cilag rais evenli split refinanc price
order bridg liquid gap break-even furthermor
assum convert bond convert assumpt
result increas outstand share total share
use valuat late-stag asset assumpt summar figur
target price nearli line current share price henc
rate share neutral
compani data credit suiss estim share price april
grey scenario look rang potenti outcom upcom
catalyst lead valuat rang per share
make follow product sale assumpt
dora eu peak sale
probabl success aprocitentan dora clazosentan japan lucerastat
cenerimod
lower sale aprocitentan dora clazosentan lucerastat
probabl success cenerimod
contrast biotechnolog compani idorsia fund consider
amount cash equip state-of-the-art facil transfer
actelion incept nevertheless compani kept spirit true biotechnolog
compani put innov top prioriti
idorsia employe work research develop compani
proprietari project four asset phase three asset phase three asset
phase also collabor reveragen/santhera duchenn muscular
dystrophi success phase data publish septemb collabor
roch immuno-oncolog major equiti stake vaxxilon ltd
believ idorsia import strength continu mani idorsia research
project stem time clozel coupl work roch contrast big
pharma project often chang manag idorsia actelion
maintain continu convict busi strategi despit actelion mani
hurdl leadership team alway show high commit compound
persever carri demerg actelion ensur employe
long term idorsia founder aim build sustain commerci organis
sale potenti forecast
idorsia manag proven scientif busi skill senior wider
manag team came across actelion time acquisit
demerg idorsia bring experi develop launch
jean-paul clozel ceo founder former ceo actelion dr clozel
start career practic cardiologist follow hoffmann-la
roch work head drug discoveri cardiovascular depart
hold medic degre receiv train pharmacolog
physiolog univers montreal canada univers california san
martin clozel chief scientif offic former head drug discoveri pharmacolog
preclin develop chief scientif offic
actelion dr clozel start career assist professor neonatolog follow
 hoffmann-la roch work scientif expert leader drug discoveri
project hold medic degre specialis pediatr neonat
intens care univers nanci franc receiv train
physiolog pharmacolog mcgill univers montreal canada univers
california san francisco us
guy braunstein head global clinic develop former head global clinic
develop actelion dr braunstein held variou execut posit
astra fison rhne-poulenc rorer glaxo wellcom gsk chiron chief
medic offic merckserono hold medic degre specialis pulmonolog
phd life scienc pari univers franc
andr mller cfo former cfo actelion mr mller held variou
financi posit includ role cfo pierr fabr sa
intern pharmaceut dermo-cosmet compani hold master degre
busi administr emlyon busi school lyon franc
simon jose mr jose held variou senior posit gsk uk us
denmark includ head global franchis platform global
presid stiefel gsk compani
andrew weiss head ir corpor commun former head ir
corpor commun actelion mr weiss start career
equiti analyst european pharmaceut warburg dillon read follow
posit analyst fund manag variou swiss intern financi
institut hold master degre busi administr monetari econom
corpor law univers zurich charter analyst
board director
jean-pierr chairman member board director three list
compani unit corpor renault radiu health inc
one unlist compani alzheon inc chairman oper unlist
compani advent intern corpor offic de lgion dhonneur knight
command order british empir
robert bertolini member board director two list compani charl
river laboratori intern inc bristol-my squibb one unlist
john greisch member board advam advanc medic technolog
associ washington us ann robert luri children hospit
david stout member board director two list compani pharnext sa
inc non-list compani nanobio corpor vaxxilon
chairman presid presid
oper gsk
vivian mong member board director one list compani ucb two
unlist compani novo hold neomedlight
thomson reuter
hold share
idorsia rich pipelin asset proceed clinic develop
includ late-stag product aprocitentan dora clazosentan lucerastat
cenerimod ponesimod vamorolon reveragen/santhera model
novel mechan action manag resist
increas preval hypertens
hypertens major risk factor heart diseas stroke two lead caus
death global resist hypertens defin blood pressur remain
level defin hypertens despit concurr administr antihypertens
therapi maxim toler dose blood pressur requir therapi
achiev control group divid three differ equal preval
subgroup true resist hypertens control resist hypertens patient
agent pseudo-resist hypertens patient elev offic blood pressur
due white-coat hypertens improp blood pressur measur medic non-
us elev blood pressur use defin mm hg howev
recent updat mm hg base guidelin american heart
associ mean adult us popul nearli million peopl
suffer elev blood pressur popul diagnos
hypertens leav unawar risk suffer resist
hypertens patient highest unmet medic need within group
true resist hypertens repres resist hypertens
patient nearli million us citizen
number slightli lower outsid unit state owe higher threshold
hypertens usual mm hg gener healthier lifestyl
geographi therefor assum adult popul europ
japan suffer hypertens assum popul diagnos
treat line us group vs us suffer
resist hypertens us assum one-third resist hypertens
patient suffer true resist hypertens
main risk factor elev blood pressur age obes diabet dietari salt
alcohol smoke drug-rel caus vitamin defici genet factor expect
hypertens popul grow slightli owe shift demograph attribut
age popul
date pharmacolog treatment avail resist hypertens
non-pharmacolog measur compris lifestyl chang smoke
cessat reduc alcohol intak healthi eat plan increas physic activ
measur typic recommend patient elev blood pressur
lack treatment explain fact therapi hypertens
addit must compos compound target complementari physiolog
mechan alreadi sever drug market treatment
hypertens potenti new treatment alreadi limit exist
standard care therapi hypertens
definit three hypertens agent use treat resist hypertens
three agent would typic includ angiotensin-convert enzym inhibitor acei
angiotensin receptor blocker arb long-act thiazid diuret calcium channel
blocker beta blocker case patient ischem heart diseas depend
three administ agent fourth drug use treat resist hypertens could
miner corticoid receptor antagonist beta blocker previous use
howev benefit therapi constrict limit efficaci advers
promis novel henc addit mechan action
aprocitentan novel dual eta etb endothelin receptor antagonist
administr oral day
least four known endothelin receptor involv control
blood pressur efficaci dual endothelin receptor antagonist regul
pressur blood vessel alreadi well known pulmonari hypertens
studi mani perform actelion research team team
recent discov new detail regard mechan action support
therapi treat hypertens insight involv fact fewer advers event
occur block receptor instead one eta even though
mechan action new gener new treatment resist
aprocitentan activ metabolit macitentan actelion drug use treat
pulmonari hypertens present blood macitentan-tr patient
preclin model show long-last efficaci aprocitentan reduc blood pressur
includ salt-sensit model phase studi result favour aprocitentan
publish may
phase studi strong result
phase studi evalu efficaci safeti toler subject
essenti hypertens test four differ dose aprocitentan
placebo lisinopril eight week studi show aprocitentan
decreas blood pressur dose-depend manner
figur aprocitentan dose-depend decreas blood pressur
dose respons consist across paramet measur statist
signific efficaci observ addit effect
statist analys follow intent-to-treat principl find
confirm randomis patient ambulatori blood pressur
discontinuit studi treatment
due advers event
case increas liver enzym
three time upper limit
case peripher edema
chang mean bodi weight kg
dose relat chang baselin
hemoglobin concentr g/l
expect decreas
phase studi result confirm dose-depend effect high toler
aprocitentan across dose similar advers event profil placebo thu
believ result support extrapol aprocitentan efficaci resist
hypertens addit fact endothelin pathway yet target
treatment resist hypertens could make drug promis asset treat
clinic relev statist signific result also contribut
success sign collabor agreement see janssen biotech inc
aprocitentan cse peak sale po
phase studi track
base phase result two dose aprocitentan select
phase trial precis studi assess short-term
efficaci aprocitentan well durabl effect long-term treatment
demonstr blood pressur lower effect aprocitentan ad standard-
of-car true resist hypertens patient
exist treatment soc standardis fix combin calcium
channel blocker amlodipin angiotensin receptor blocker valsartan diuret
hydrochlorothiazid studi design close collabor fda
part demonstr blood pressur lower effect ad soc
part ii evalu long-term safeti toler
part demonstr effect blood pressur durabl
primari endpoint chang baselin week double-blind treatment
trough sit systol blood pressur measur aobpm autom offic blood
patient randomis approxim patient expect complet
entir studi studi conduct approxim site around
countri expect studi finish end
previous describ patient popul repres snapshot expect
patient popul elev blood pressur increas slightli futur due
shift demograph also expect percentag resist hypertens patient
increas due precis diagnost tool higher awar among physician
popul larg
base assumpt estim target popul us
europ japan combin
averag us patient resist hypertens around yearli medic
cost vs averag patient nonresist hypertens cardiolog
news januari link assum yearli gross cost aprocitentan
us ex-u respect furthermor assum
world-wide peak penetr aprocitentan would impli world-wide peak
sale us ex-u respect
peak royalti
base lack exist therapi indic statist signific
clinic relev phase data experienc manag team strong
global partner assum probabl success industri
averag stage
hypertens age
hypertens age
diagnos treat
gener drug treat insomnia
high preval insomnia
insomnia common sleep disord world roughli gener
popul suffer sleep disrupt approxim popul
associ symptom daytim function impair accord nation
institut nih peopl age affect younger peopl
femal affect male besid person impact sleep depriv
cost economi billion dollar year impact lack sleep
product health cost us per year
countri tuck sleep novemb link
chronic insomnia defin difficulti initi maintain sleep non-restor
sleep despit adequ opportun sleep insomnia classifi transient
acut chronic transient last less week acut less month
chronic last longer month peopl insomnia usual stay awak
long time fall asleep wake often night difficulti go
back sleep wake earli morn feel tire upon wake show poor
concentr abil next day etc
caus insomnia divers rang psycholog problem
physiolog stress chronic pain heart failur menopaus extern
influenc caffein nicotin alcohol
treatment option insomnia divers caus sleep hygien
lifestyl chang usual first treatment appli measur
unsuccess cognit behavior therapi ad follow pharmaceut
treatment due mani advers effect high addict rate current treatment
option pharmaceut therapi gener recommend period
four five week
main goal medic insomnia treatment improv speed sleep onset
restor natur sleep pattern avoid next-day hangov effect side
effect addict unmanag drug-drug interact contemporari medic
treatment typic split two group prescript fda-approv treatment
non-prescript over-the-counter treatment fda-approv treatment includ gabaa receptor
antagonist benzodiazepin non-benzodiazepin sedat antidepress
melatonin antagonist dual orexin receptor antagonist commonli use
over-the-counter drug includ antihistamin valerian l-tryptophan over-the-counter drug popular
howev sever undesir side effect dri mouth blur vision
constip tachycardia next-day impair
benzodiazepin non-benzodiazepin gaba agent
insomnia prescript drug belong group benzodiazepin estazolam
quazepam triazolam flurazepam temazepam non-benzodiazepin also known
z-drug
zaleplon zolpidem eszopiclon differ
benzodiazepin non-benzodiazepin relat select differ type
gabaa receptor exactli promot sleep unknown howev common
class may global reduc cortic activ thu make difficult
excitatori neurotransmitt gener action potenti big challeng classic
gaba-medi medic insomnia half-liv differ compound
treatment long half-lif caus residu sleepi next-day
hangov effect treatment short half-lif may persist within bodi
suffici period maintain sleep side effect thu broad includ
vomit complex sleep behavior abnorm thought behavior suicid
thought action increas aggress worsen depress name
addit gaba agent danger taken togeth opioid
combin induc respiratori depress dizzi even death given opioid
addict epidem us high addict potenti gaba agent lead
concern new epidem prescript number gaba agent declin
second class prescript drug sedat antidepress serotonin antagonist
norepinephrin reuptak inhibitor first fda-approv antidepress indic
treat sleep mainten insomnia tricycl antidepress tca dopexin
sleep promot properti dopexin might attribut anti-histaminerg effect
potent histamin receptor antagonist drug may promot sleep block
wakefulness-rel neurotransmitt serotonin promot well-b
happi norepinephrin promot alert acetylcholin promot attent
motiv despit posit characterist sleep improv rebound insomnia
addict side effect still pronounc sedat gastrointestin side
effect hypertens abnorm thought behavior complex sleep-rel
behavior although antidepress popular hypnot littl clinic
research done efficaci safeti treatment insomnia
melatonin agonist third group agent use treat insomnia
melatonin natur occur hormon produc nighttim enhanc
sleep-promot effect sedat lower core bodi temperatur reduct sleep
latenc increas total sleep time fda-approv melatonin agonist
ramelteon improv sleep onset latenc reason limit side effect
headach dizzi sore throat
last newest class insomnia medic dual orexin receptor antagonist
orexinerg system describ link sleep disord narcolepsi late
sinc receiv promin place sleep research contrast
sleep-promot agent orexin system directli involv promot sleep onset
mainten instead play key role promot wake across speci
orexin peptid highli conserv vertebr orexin neuron activ peak
normal wake period fall silent normal sleep period
patient narcolepsi tend fewer orexin-produc neuron show
chronic reduc level orexin cerebrospin fluid orexin system
promot arous block potenti promot sleep addit orexin
system block arous system assum doesnt influenc sleep pattern
henc could induc normal sleep caus fewer side effect oppos gaba
agent directli influenc sleep pattern shut brain besid
fewer orexin receptor brain oppos wide distribut gaba receptor
may contribut focus drug effect fewer side effect
discoveri orexin signal system new promis target pharmaceut
develop treatment insomnia reveal
two excitatori neuropeptid orexin orexin bind two differ protein-
coupl receptor howev oxa bind receptor oxb
select bind addit orexin receptor differ locat
throughout central nervou system led assumpt two
orexin receptor play differ role mainten wake studi
differ compound proven assumpt
singl orexin receptor antagonist sora block limit effect
sleep induct howev agent proven use treatment substanc
abus withdraw obes panic disord sora-block contrast could
facilit induct sleep howev less pronounc manner case
dual orexin receptor antagonist dora dora agent prove strongest
charl martineau univers toronto figur summari fda-approv sleep agent show side effect fda-approv drug
mechan action
posit alloster modul
posit alloster modul
loss coordin
danger combin opioid
plu
abnorm thought behavior
abnorm thought behavior
hormon effect decreas interest sex
abnorm thought behavior
dora clinic trial indic promis superior characterist
idorsia research team long experi dora-bas sleep agent
actelion dora drug almorex abandon drug-drug interact
statin observ phase studi howev result
formul screen test process develop new dora
drug dora novel dual orexin receptor antagonist dosag eight time lower
almorex preclin data suggest dora may normalis sleep
architectur figur low potenti abus
charl martineau univers toronto figur rat eeg data sleep efficaci architectur time spent sleep wake stage total time
first activ phase follow administr
phase data show dora ideal pharmacokinet pharmacodynam
profil insomnia drug take hour reach steadi state figur
rapid sleep onset hour appropri durat action
hour figur potenti next-day hangov effect figur
phase studi conduct trial perform one
adult patient one elderli patient treatment period one month
studi show dose-depend respons primari endpoint waso figur
charl martineau univers toronto figur clinic relev effect well occurr
seriou advers event relat treatment studi result confirm
efficaci safeti dora phase studi adult patient also examin
efficaci dora activ compar zolpidem result show
improv efficaci dora vs zolpidem
figur chang waso baselin day
adult patient
figur chang waso baselin day
elderli patient
phase studi adult patient confirm preserv normal sleep
architectur dora oppos sleep architectur achiev current
standard care zolpidem figur clinic relev find
demonstr dora littl impact sleep pattern rather dora induc
sleep affect wake system suggest patient consolid
memori restor brain activ sleep way healthi individu
henc wake refresh next morn case
recruit double-blind randomis placebo-control parallel-group
polysomnographi phase studi start summer patient experi highli
valu studi next-day perform feasibl restor normal
sleep pattern phase patient per arm enrol site
across countri patient age year older treatment
period three month two efficaci studi nine month extens
studi program investig three dose two trial
placebo one trial evalu treatment dose
month trial measur treatment dose
month extens studi measur three dose gener data
long-term treatment insomnia
commerci potenti possibl competit lemborex
publish phase see figur figur figur phase see
figur figur data appear compar believ pharmacolog
differ translat meaning clinic differenti shorter half-lif well
time reach steadi state could provid similar efficaci lower next-day residu
effect dora
lemborex dual orexin receptor antagonist dora treatment insomnia disord result bayesian adapt
randomis double-blind placebo-control studi journal clinic sleep medicin volume page patricia murphi
figur phase data suvorex studi
chang baselin month
month
month
month
month
mean chang month treatment
half-lif time steadi state known suvorex dora
publish lemborex howev eisai/purdu conduct addit phase studi
see lemborex step ahead suggest lemborex pharmacolog
profil superior suvorex us abl compar lemborex dora
concret data need howev due lower profil cf figur suvorex
versu dora due promis data addit phase lemborex
perceiv much competit threat fda-approv dora agent
suvorex belsomra market merck eisai lemborex
dora suggest superior pharmacolog profil compar suvorex
sub-optimal pharmacolog profil suvorex reflect fda approv
primari endpoint two phase studi compar high suvorex dose
versu placebo suvorex approv lower dose
higher dose found similar efficaci lower dose significantli
advers event somnolesc day dose suicid ideat abnorm
sleep behavior other howev label even approv dose rang
contain next day limit warn fact suvorex impair drive
skill patient use lower dose caution next day
drive activ requir full mental awar
effect explain pharmacolog properti half-lif around
hour hour reach steadi state mean stay system hour
non-linear kinet potenti multipl drug interact particularli
antidepress antipsychot ideal hypnot
oppos suvorex dora shorter half-lif metabolis much faster
figur fast onset action appropri durat action figur
figur profil comparison dora suvorex accord label
time reach steadi state
therefor despit fact alreadi establish time dora launch
see seriou competit come suvorex
contrast suvorex see competit come eisais/purdu dora
nda fda alreadi file pdufa date set decemb
mean could potenti launch even dora phase data
publish lemborex studi also suggest better pharmacokinet
dynam profil lemborex compar suvorex
nda base two phase studi sunris sunris total
test adult patient
sunris one-month studi elderli patient lemborex zolpidem
placebo achiev primari key secondari endpoint versu placebo
versu activ compar zolpidem studi measur object assess
sleep paramet time sleep onset sleep effici waso includ time spent
awak second half night common complaint elderli
sunris studi lemborex placebo enrol adult
patient subject assess abil fall asleep stay asleep base
patient self-report sleep diari six-month result present februari see
figur demonstr statist signific improv subject sleep onset
latenc primari endpoint subject sleep effici subject waso key
addit phase trial two phase studi conduct studi met
primari endpoint demonstr postur stabil clinic meaning
wors zolpidem compar treatment arm lemborex healthi
elderli subject studi also measur quickli particip could return sleep
awaken lemborex prove equal placebo studi also
achiev primari endpoint evalu next morn impair measur adult
elderli subject drive perform studi show clinic
meaning statist signific impair drive perform compar
placebo also show drive perform impair patient take
zolpidem compar placebo
believ studi suggest lemborex potenti superior
profil suvorex
howev see risk commercialis purdu subject
signific neg public relat role market opioid oxycontin march
purdu member sackler famili compani agre pay
settl lawsuit brought state oklahoma reuter march
accord press report reuter march purdu consid file
bankruptci given number lawsuit compani face although purdu like
right experi resourc promot lemborex believ first
need sort legal challeng eisai cover japan pharma team
forecast lemborex peak sale
prescript insomnia drug issu last year accord iqvia
million prescript gener brand drug
sale came gener figur figur
rh
sale usd rh
commonli prescrib insomnia drug gaba agent mainli
characteris high addict rate loss memori howev despit fact
gaba agent less ideal insomnia drug gaba drug prescript increas
earli reach peak number prescript declin
medic associ american medic associ rais
possibl gaba-induc epidem threat similar opioid addict epidem
associ also highlight danger combin opioid gaba agent
could lead respiratori depress dizzi death howev declin
gaba agent prescript mean peopl stop take insomnia drug
case opioid mani peopl found way get elsewher
due promis properti dora agent high unmet medic need
new effect non-addict mechan assum percentag gener
market share go lose share dora agent
data alreadi exist show suvorex absolut sale number
increas sinc launch figur expens gener
charl martineau univers toronto figur suvorex sale sinc launch
lh
sale usd rh
suvorex also take consider market share within brand market figur
figur notabl given non-id profil suvorex describ
previou section efficaci dora agent support lemborex
mention see competit threat come lemborex rather
suvorex howev posit side lemborex could also educ
market creat ideal condit entranc new dora agent idorsia
dora besid see risk commerci collabor eisai purdu due
purdu legal challeng given substanti market size high unmet
need non-addict effect insomnia agent fewer side effect believ
space one dora agent last least idorsia alreadi
prove abil creat market pah actelion demonstr manag
strong commerci execut skill believ phase data dora confirm
superior potenti standard care insomnia
brand insomnia drug market share us
assum dora take market share peak us see figur
figur histor cs forecast market share split us brand
other gaba then new gener drug
iqvia credit suiss estim
rel us eu assum lower market share japan due eisai
furthermor assum probabl success us jp eu due
challeng regulatori environ dora line expect
dora approv confid substanti growth dora
would expect drug prescrib gener practition sizeabl sale
forc like requir effect promot idorsia current
sale forc accord manag plan establish one time
expect idorsia keep much valu drug candid possibl
enter co-promot partnership suitabl compani success phase
studi henc model econom sale compound correspond
mileston po
dora trx market share brand
associ
charl martineau univers toronto figur moder sever cerebr vasospasm digit subtract
prevent effect clazosentan cerebr vasospasm clip surgeri aneurysm subarachnoid hemorrhag
japanes korean patient cerebrovasc doi miki fujimura et al fig
preval region differ
aneurysm subarachnoid haemorrhag asah ruptur aneurysm blood-
fill bulg wall brain arteri lead bleed subarachnoid space
protect layer around cerebr cortex endovascular coil
neuroradiolog intervent microsurg clip procedur neurosurgeri use
stop bleed cerebr vasospasm constrict cerebr arteri result
diminish blood flow brain may lead sever brain damag vasospasm
major caus morbid mortal associ asah occur insidi
within first two week asah
estim world-wide incid asah persons/year region
variat exampl incid japan time higher global
averag yet gener understood risk ruptur higher japan
us incid intracrani aneurysm lower henc asah
patient popul japan us name patient
patient around die reach medic care remain
patient treat around experi cerebr vasospasm day
asah
lack understand lead ineffici treatment option
occurr vasospasm asah still complet understood
evid howev physiolog mechan signal molecul nitric
oxid endothelin regul cerebr arteri diamet alter product
break red blood cell exampl harm endotheli cell normal produc
vasodilatori nitric oxid reduc nitric oxid subarachnoid space also
observ elev amount endothelin vasoconstrictor affect
area asah
given multipl complex unclear factor lead vasospasm
known method prevent singl effici treatment market
therefor medic treatment often variat known therapi includ
rescu therapi invas intra-arteri intervent associ increas
risk often requir repeat procedur pharmacotherapi triple-h
therapi calcium channel blocker japan approv drug fasudil ozagrel
nicardipin howev none prove effici treatment
triple-h therapi includ treatment hypertens hypervolemia haemodilut
often ad hyperdynam treatment goal increas cerebr blood flow
extens intravascular volum reduct blood viscos howev
although therapi might benefici impact outcom vari due lack
standardis administr addit therapi costli caus
complic cardiopulmonari failur exacerb cerebr oedema renal
failur hypovolemia sepsi risk untreat aneurysm ruptur
contrast h-therapi oral prophylact treatment nimodipin safe cost-
effect sever gener market alreadi nimodipin calcium channel
blocker select vascular smooth muscl largest studi show
reduct cerebr infarct reduct poor outcom three month
compar placebo nimodipin current fda-approv drug treat
cerebr vasospasm although nimodipin might improv outcom vasospasm
prevent revers despit temporari improv medic
condit describ treatment long-term neurolog outcom remain
clazosentan challeng studi design limit region likelihood
clazosentan endothelin receptor antagonist block eta receptor bind
endothelin potent vasoconstrict peptid administ intraven
consciou seri phase prevent vasospasm
clazosentan investig phase studi consciou two phase
studi consciou ii year ago
consciou randomis double-blind placebo-control dose-find studi
assess efficaci safeti intraven
clazosentan primari endpoint reduct cerebr vasospasm-rel
morbid mortal caus secondari endpoint effect
function outcom measur gose glasgow outcom scale extend result
show dose-depend reduct moder sever angiograph vasospasm
placebo group clazosentan group primari
endpoint effect function outcom measur gose secondari endpoint
observ pulmonari complic hypotens anaemia common
dose clazosentan placebo howev ae manag
consid sever studi result enabl phase studi consciou ii
phase studi aim show clazosentan-induc reduct
incid prevent cerebr vasospasm-rel morbid all-caus mortal
consciou ii patient underw surgic clip show
signific effect clazosentan treatment primari reduct vasospasm-
relat event within six week post asah secondari gose week post asah
endpoint consciou ae pulmonari complic hypotens
increas treatment find signal stop consciou studi
patient undergon coil howev plan patient
enrol consciou alreadi result shown signific
rel risk reduct vasospasm-rel morbidity/all-caus
mortal clazosentan group within six week post-asah addit
significantli reduc incid delay ischaem neurolog deficit dind
rel risk reduct clazosentan group led
reduc use rescu therapi group howev consciou
studi effect function outcom week measur gose
side effect lung complic hypotens anaemia observ
revers new phase treatment vasospasm
base studi new proof-of-concept phase studi revers
design show revers angiograph confirm cerebr vasospasm patient
asah treat endovascular coil clip henc new studi aim
evalu efficaci safeti treatment cerebr vasospasm oppos
prevent vasospasm-rel morbid all-caus mortal previou
studi revers complet compani share result
regulatori author order design phase
react new phase lesson previou trial implement key
react double-blind randomis placebo-control parallel-group phase studi
assess efficaci safeti clazosentan prevent clinic deterior
vasospasm-rel delay cerebr ischaemia adult patient asah even
though lesson learnt consciou seri discuss health
author us eu studi design primari secondari endpoint
challeng accord manag
primari endpoint occurr clinic deterior due studi
drug initi day post-studi drug initi compar time frame six
week post asah consciou seri secondari endpoint
occurr all-caus new worsen cerebr infarct day post-studi
drug initi assess gose week post-asah
consciou seri
around patient treat clip coil enrol site across
countri treatment paradigm clazosentan placebo treatment
period day studi expect run around month expect studi
result
although appreci lesson consciou seri implement
visibl primari endpoint concern need gose
assess secondari endpoint seen improv yet
doubt whether improv even shown given ethic
circumst see gener comment clinic trial owe difficult
regulatori environ assign probabl success clazosentan ex-
japan see commerci potenti like japan
registr japan promis outcom
addit revers studi phase studi complet japanes
korean patient underw surgic clip japan asah treat mainli
neurosurgeon studi design evalu occurr cerebr
vasospasm patient asah henc prevent vasospasm
prevent effect clazosentan cerebr vasospasm clip surgeri aneurysm subarachnoid hemorrhag
japanes korean patient cerebrovasc doi miki fujimura et al fig
among patient complet studi incid vasospasm day
asah onset placebo group clazosentan
group clazosentan group indic signific reduct
vasospasm two clazosentan group vs placebo
clazosentan group primari endpoint secondari endpoint occurr
newli form cerebr infarct associ vasospasm within six week asah
onset assess gose week asah onset wherebi
signific reduct newli form infarct clazosentan group
differ clazosentan placebo group seen assess gose
furthermor studi includ exploratori endpoint overal incid all-caus
death and/or vasospasm-rel morbidity/mort reduc significantli
clazosentan group compar placebo group term
advers event clazosentan group show higher number lung
complic hypotens anaemia placebo
overal incid death vasospasm-rel morbid pp
prevent effect clazosentan cerebr vasospasm clip surgeri aneurysm subarachnoid hemorrhag japanes korean patient cerebrovasc
encourag posit result phase studi japan idorsia start market
registr programm countri market registr trial follow
design evalu reduct occurr cerebr vasospasm vasospasm-
relat morbid mortal event patient asah treat surgic clip
trial coil trial respect patient randomis either
clazosentan placebo maximum day follow onset
compani state japanes regulatori author co-
oper us european author owe like strong neurosurgeon lobbi
high unmet need japan highest asah incid rate
world one reason one trial achiev statist signific
result order receiv market approv japan prevent vasospasm
persist attent gose assess reason given
idorsia establish subsidiari idorsia pharmaceut japan june
assign probabl success phase studi japan expect result
studi publish
gener comment clinic trial
complet discuss clinic trial highlight complic
occur across trial lack impact gose advers event pulmonari
complic hypotens anaemia
first lack effect gose trial may caus fact rescu
therapi appli often placebo group studi japan rescu
therapi employ twice mani time placebo group
almost four time mani time placebo group employ
rescu therapi may dilut treatment effect clazosentan week howev
option compar aspect fail administ rescu therapi would
ethic
second advers effect might attribut properti eta-select
antagonist studi conduct actelion group martin clozel demonstr
contrast dual eta etb receptor blockad eta-select antagonist lead
greater increas vascular permeabl lung complic oedema
over-activ non-antagonis receptor etb receptor explain
occurr advers effect clazosentan trial contrast absenc
aprocitentan trial dual endothelin antagonist block receptor
howev given vasospasm life-threaten condit adjunct
therapi reduc side effect potenti posit clazosentan far outweigh
advers impact
commerci potenti like japan
see robust market potenti japan clazosentan owe follow
patient popul larg us unmet medic need high none
three drug approv japan fasudil ozagrel nicardipin prove
effici prevent vasospasm asah treat mostli surgic
clip rather invas coil neurosurgeon lobbi strong japan
believ reason japanes regul seem co-
oper us european counterpart regard clazosentan approv
condit treat neurosurgeri centr impli small
salesforc assum target popul patient japan moreov owe
high unmet medic need lack signific competit drug label state
prevent vasospasm assum market share price
per treatment arriv peak sale idorsia conduct two phase
studi japan one requir show statist signific result
approv idorsia establish idorsia pharmaceut japan june
assum probabl success japan go-to-market strategi without
contrast japanes market us eu market look differ see react
new phase treatment approv prevent vasospasm us
eu assum peak market penetr ex-japan eu price
net price us base
assumpt arriv ex-u peak sale addit compani
state discuss studi design endpoint health author us
europ complic reflect point assign probabl
success clazosentan us europ
drug orphan-drug statu japan howev believ
come approv common procedur japan drug orphan drug
statu us eu
us patient popul asah
develop vasospasm eu japan
fabri diseas progress x-link rare genet diseas caus defici
dysfunct enzym -galactosidas enzym respons break
wast product call globotriaosylcerimad patient fabri diseas
enzym work properli result broken
instead accumul cell bodi lysosom storag diseas
accumul lysosom cell blood vessel skin eye gastrointestin
system kidney heart central nervou system lead wide rang
symptom neuropath pain gastrointestin problem skin rash heart
diseas symptom typic first occur childhood often difficult classifi
non-specif symptom togeth rare occurr diseas often
lead misdiagnos life expect patient fabri diseas year
male year femal common caus death
figur mechan fabri diseas dysfunct absent
galactosidas result accumul variou organ
patient world-wide suffer fabri diseas around
patient europ us remain row
current treatment compris enzym replac therapi ert enzym
stabilis therapi haemodialysi and/or kidney transplant often necessari
ert intraven administ iv treatment suppli defici enzym
galactosidas cell treatment given everi two week although
consider difficulti link possibl unwant immun respons
bodi enzym iv infus uniform result uneven
distribut enzym within bodi addit enzym quit big
molecul henc necessarili enter cell especi cell therefor
littl effect neuropath pain one main burden diminish
qualiti life fabri patient ert cure lifelong treatment
improv metabol partial prevent diseas progress potenti revers
symptom us one ert drug approv fda name
fabrazym market sanofi europ two ert drug approv name
fabrazym replag market sanofi shire respect
enzym stabilis therapi target patient amen mutat enzym
-galactosidas mutat drug act chaperon stabilis
dysfunct -galactosidas allow enzym transport area
cell break drug avail categori oral
administ galafold market amicu therapeut galafold receiv ema
approv approv fda august
lucerastat focu reduc neuropath pain
lucerastat small-molecul iminosugar inhibit glucosylceramid synthas gc
figur aim reduc product glycosphingolipid includ
small enough enter cell henc potenti posit impact
neuropath pain contrast ert lucerastat administ oral twice day
figur mode action lucerastat substrat reduct therapi
safeti toler pharmacodynam pharmacokinet evalu fabri
diseas patient open-label randomis phase studi patient receiv
lucerastat bid twice day addit ert four patient receiv ert
treatment durat week mean plasma level metabol substrat
glucosylceramid glccer lactosylceramid laccer globotriaosylceramid
plasma urin measur baselin result show clear lower
valu lucerastat group vs placebo overlap two studi group figur
lucerastat bid well toler patient fabri diseas eight
patient report advers event lucerastat group clinic relev safeti
abnorm observ regard lucerastat one seriou advers event
occur relat lucerastat
believ data show clear clinic effect lucerastat diseas without
seriou advers effect given combin ert also demonstr
drug-drug interact soc make ideal candid combin therapi
design phase studi modifi present may contrast
studi evalu addit effect lucerastat ert phase studi
evalu efficaci safeti lucerastat oral monotherapi adult fabri patient
double-blind randomis placebo-control parallel-group studi around
patient expect enrol site across nine countri
randomis ratio either lucerastat placebo
primari studi object determin effect lucerastat neuropath pain
measur idorsia valid fabri diseas pain instrument
secondari object determin effect lucerastat gastro-intestin
symptom abdomin pain diarrhea confirm effect lucerastat biomark
fabri diseas compar phase studi determin lucerastat safeti
toler treatment durat six month bid end
double-blind period patient given option enter open-label extens
neuropath pain one first symptom fabri diseas often occur
childhood accord manag paediatr studi children age year
plan start shortli
believ meaning object one hand
determin six month treatment patient still perceiv pain drug simpli
effect hand clinic relev fabri patient
report neuropath pain form frequent pain moder sever pain pain
hand feet addit none exist therapi fabri focus
expect studi result publish
lucerastat commerci potenti first-lin potenti
assum world-wide fabri patient popul patient
undiagnos diagnos patient treat us
market account fabri popul europ rest spread
across world assum diagnos well treat patient number rise
owe access medic care broader physician educ awar
well conveni administr current therapi oral vs iv
chronic diseas life-long treatment like reimburs
payer assum high complianc rate small number switcher lucerastat
due conveni oral administr drug dampen effect
neuropath pain price depend form therapi whether
monotherapi combin therapi ert drug assum
monotherapi assign yearli gross price us ex-
us slightli enzym stabilis therapi galafold due specif
efficaci lucerastat neuropath pain also premium ert owe
addit benefit oral administr model peak market share
us vs europ approv ert option europ us vs
japan home-bas ert approv japan vs row base
assumpt arriv global peak sale assum
probabl success industri averag clinic stage although
cautiou primari endpoint phase studi neuropath
pain specif measur phase believ primari endpoint
reach commerci potenti would substanti pain main factor limit
qualiti life fabri patient
assum compani commercialis drug without partner would requir
small sale forc
drug orphan drug statu us europ
system lupu erythematosu sle common form lupu
autoimmun diseas bodi immun system mistakenli attack healthi tissu
mani bodi part result symptom vari person person includ
pain swollen joint chest pain hair loss mouth ulcer swollen lymph node
feel tire red rash commonli face increas mortal
compar gener popul symptom appear cyclic period
relaps flare altern period remiss caus sle clear
might involv genet environment factor lymphocyt also believ
play import role diseas
diseas usual begin age patient surviv
year new treatment major patient die cardiovascular
divers symptom make diseas difficult diagnos rate sle vari
countri ethnic sex chang time rang
peopl women childbear age affect around nine time often
men african caribbean chines peopl affect caucasian
peopl lowest rate occur japan iceland highest us
franc rate develop countri unknown
lupu broad rang treatment option broad rang
cure sle current treatment limit base anti-
inflammatori immunosuppress therapi may includ nsaid nonsteroid
corticosteroid b-lymphocyt stimul protein inhibitor lifestyl chang
avoid sunlight exacerb skin manifest diseas fatigu
activ support pharmaceut treatment kidney inflam patient may
need kidney transplant even though rang new therapi treatment method
increas time still high medic need effect medic
cenerimod activ immunomodul
cenerimod potent once-daili oral administ potent select modul
reduc number circul infiltr t- b-lymphocyt without affect
matur memori expans prevent leav lymph node
could potenti also use treat autoimmun diseas receptor also
involv motil cancer cell
safeti toler pharmacodynam pharmacokinet evalu
adult sle patient randomis double-blind placebo-control dose-respons
phase studi sixty-seven enrol patient receiv either daili dose
cenerimod placebo period week result
publish may show dose-depend reduct lymphocyt drug
well toler dose level occurr advers event similar
five treatment group
result support continu clinic studi dose-find phase
initi decemb placebo-control studi evalu
efficaci safeti four dose cenerimod randomis
ratio given varieti symptom cyclic occurr season
influenc sun summer challeng recruit patient right time
expect phase result studi appoint track develop
design fda
owe differ racial distribut us vs europ treat
patient us vs treat patient europ sle manifest numer
symptom henc difficult diagnos assum number treat patient
grow slightli owe better physician educ awar
number therapi sle rather high explain broad rang
symptom yearli cost treatment vari accordingli rang
gener corticosteroid anti-malaria hydroxychloroquin sulphat
benlysta averag treatment cost per patient
seriou kidney complic involv assum cerenimod gross price
us europ peak market penetr
us europ base assumpt arriv world-wide peak sale
accord manag asset could potenti also appli
indic therefor assum compani partner drug
develop registr commercialis phase studi complet
model econom sale well chf mileston po
probabl success approv us well europ
averag asset phase
us
eu
addit late-stag programm idorsia extens early-stag pipelin
three programm current phase two phase addit cenerimod
asset earli develop carri high risk thu
includ model
mechan action
ponesimod cse peak sale po
idorsia actelion johnson johnson revenue-shar agreement
term entitl idorsia receiv aggreg net sale actelion product
ponesimod quarterli basi
ponesimod oral activ select receptor immunomodul
investig treatment relaps multipl sclerosi rm phase studi
optimum point on-going studi multi-centr randomis double-
blind parallel group studi optimum compar efficaci safeti ponesimod
teriflunomid patient rm point compar efficaci safeti
ponesimod versu placebo patient activ rm treat tecfidera
expect readout optimum studi end point studi
end model potenti first sale peak sale
janssen biotech inc aprocitentan cse peak sale po
idorsia sign collabor agreement decemb agreement
describ develop commercialis aprocitentan deriv
compound product
parti joint right regard develop aprocitentan idorsia
supervis phase develop regulatori submiss aprocitentan
treatment resist hypertens supervis phase develop
regulatori submiss addit indic cost share equal
two parti follow way idorsia respons share
develop submiss aprocitentan fund idorsia share
develop submiss addit indic fund
deduct correspond royalti pay idorsia
insuffici royalti becom due idorsia respons shortfal
idorsia respons receiv market approv aprocitentan
treatment resist hypertens us eu respons
market approv indic sole right commercialis
product collabor market
idorsia receiv one-tim mileston payment recognis
two part recognis immedi contract revenu fourth
quarter remaind mileston payment recognis contract
revenu next three year
addit pay idorsia aprocitentan royalti amount
annual net sale
annual net sale
annual net sale
reveragen vamorolon cse peak sale po
idorsia inherit collabor agreement reveragen actelion
agreement sign april regul research co-develop
vamorolon non-hormon steroid modul treatment duchenn muscular
dystrophi dmd therapi link particular mutat
potenti administ boy age vamorolon profil suggest superior
muscl strength membran stabilis two key efficaci aspect dmd therapi
lower side effect profil current standard care therapi
glucocorticoid vamorolon grant orphan drug statu fda
ema receiv track design fda
four dose level two-week treatment period
month extens studi dose level vamorolon old boy
studi complet earlier year show dose-rel improv multipl
function test strength endur clinic efficaci demonstr
vamorolon dose compar data untreat
patient cinrg duchenn natur histori studi similar magnitud
seen prednison glucocorticoid -treat patient histor cinrg
prednison trial vamorolon show limit metabol disturb bone turnov
chang dose
reveragen initi double-blind placebo- prednisone-control clinic trial
vamorolon august enrol first patient studi enrol
approxim steroid-nav patient age year site studi design
consist
vamorolon prednison
placebo initi treatment period later prednison
placebo group cross low- high-dos vamorolon second
treatment period patient vamorolon second treatment period last
addit week enrol expect take month total studi
durat month data expect
idorsia option obtain world-wide licenc right vamorolon
exercis option time later upon receipt phase studi
result consider exercis idorsia pay reveragen
regulatori commerci mileston dmd indic three one-
time sale mileston payment aggreg furthermor reveragen
also entitl receiv mileston approv
commercialis three indic upon commercialis idorsia
pay increas tier single-to double-digit royalti net sale vamorolon
santhera vamorolon cse peak sale po
novemb idorsia enter agreement santhera
santhera acquir option obtain exclus sublic vamorolon
indic territori except japan south korea
non-refund consider enter agreement santhera paid idorsia
new regist share santhera pharmaceut hold ltd exist authoris
share capit fair market valu subject lock-up provis
up-front payment cash idorsia hold share santhera current
therefor santhera biggest sharehold
santhera may exercis option upon receipt phase data follow one-
time consider idorsia option exercis idorsia entitl
regulatori commerci mileston payment dmd indic
four one-tim sale mileston payment aggreg furthermor
idorsia entitl addit regulatori commerci mileston payment
aggreg three indic upon commercialis santhera
pay idorsia tier royalti rang single-digit low-double-digit percentag
annual net sale vamorolon
earli assum anyth three addit indic vamorolon
includ potenti mileston model yet
decemb idorsia sign research collabor agreement roch
grant roch exclus option right develop market compound new
approach field cancer immunotherapi basi agreement idorsia
term agreement roch pay idorsia up-front amount
option exclus licens idorsia compound well
collabor payment exercis roch
exclus world-wide licenc develop commercialis idorsia roche-
return idorsia receiv one-tim develop regulatori mileston
well one-tim mileston base sale threshold tier royalti
annual net sale product result collabor
believ earli includ potenti mileston
model howev expect roch continu collabor pay
idorsia hold major equiti stake vaxxilon also inherit actelion
actelion establish vaxxilon ag aim discov develop
commercialis carbohydr vaccin vaxxilon incorpor swiss law
togeth max planck societi seeberg scienc gmbh privat compani
germani actelion major sharehold hold vote interest
compani vaxxilon licens exclus right multipl preclin vaccin
candid addit technolog mpi
specif upcom cost connect vaxxilon includ model
use patient-bas model estim size address market
deriv sale forecast use market share price assumpt
forecast sale royalti correct probabl success assumpt
figur forecast revenu composit econom risk-adjust usdm
idorsia portfolio well balanc view term timelin launch
three import asset term potenti revenu aprocitentan dora
even though aprocitentan licens alreadi expect dora out-
licens well biggest contributor forecast revenu owe
larg market high unmet medic need new therapi model
aprocitentan reach peak sale faster dora stay plateau
entranc gener potenti competit product except
high unmet medic need aprocitentan competitor current dora like
reach peak sale slowli given differ dynam within insomnia market
first entir insomnia market compris gener current second
expect two dora agent brand market launch dora
assum howev dora win consider market share improv
formul lead enhanc mechan action drug assum
commercialis partner contract aprocitentan commercialis
place alreadi
lucerastat also contribut consider idorsia revenu owe mainli lack
adequ competitor treatment neuropath pain associ fabri diseas
even though idorsia start busi cash day
gross cash balanc sheet decemb expect
compani reach break-even earliest
compani issu non-gaap opex guidanc guidanc
increas driven mainli four on-going phase
programm well grow commerci organis compani
continu grow phase programm enter phase coupl year opex
unlik declin howev align expens probabl success
correspond asset appli probabl market sale expens
clazosentan cenerimod two asset assum idorsia commercialis
salesforce/without partner
nevertheless see need capit assum compani make use
current undrawn credit line cilag yearli
cash burn see need capit model
capit rais howev believ
posit phase result publish idorsia might abl also use
option rais capit royalti bank said accord model
capit rais discount refinanc price would dilut share
outstand almost
figur net gross cash oper profit idorsia
fund rais
note gross cash includ convert loan idorsia receiv convert bond idorsia issu credit
line cilag assum idorsia draw
idorsia provid loan cilag june loan
convert aggreg share capit time loan provid
carri interest term year first tranch
convert convert alreadi repres issu share
decemb remain amount potenti convert
share convers price assum loan convert
would expect dilut idorsia share
idorsia issu senior unsecur convert bond juli
bond term six year interest rate per annum convers
price result share assum bond convert
potenti dilut idorsia share less accord
idorsia share outstand decemb
assum capit rais result
share assum refinanc share price potenti dilut
convers convert bond result addit share
convers loan result share aggreg
addit share would result dilut around
share
charl martineau univers toronto figur idorsia cash flow statement chfm
non-cash accret convert loan/bond discount
unreal loss market secur
chang work capit
net cash oper activ
purchas sale short-term deposit
purchase/ sale long-term deposit
gross purchas pp
invest intang asset acquisit
purchas market secur
net cash invest activ
payment dividend
chang sharehold equiti capit rais issuanc new
proce demerg
proce issuanc convert loan net cost
proce issuanc convert bond net cost
net cash financ activiit
unrealis fx gain loss cash cash equival
net chang cash cash equivalet
cash equival begin year
cash equival end year
figur idorsia balanc sheet chfm
short-term invest
holt methodolog use proprietari perform measur known
return invest cfroi approxim econom return
estim averag real intern rate return earn firm portfolio
project constitut oper asset firm cfroi compar directli
real cost capit investor real discount rate see firm creat
econom wealth remov account inflat distort cfroi allow
global compar across sector region time also comprehens
metric tradit roe holt valuat base discount
link forecast holt indic warrant price
line target price note holt default discount rate
higher eu pharma averag market-impli discount rate attribut
idorsia size leverag
beyond explicit forecast period holt use fade-dcf model arriv
warrant price fade cfroi growth respect long-term observ level
incorpor econom realiti competit
sale growth parallel point chang forecast
price book
credit suiss holt cfroi holtar trademark regist trademark credit suiss group ag affili unit state countri
display purpos sale growth ebitda chart cap
compani data credit suiss estim credit suiss holt current price april
cfroi discount rate
asset growth
peer global databas captur uniqu inform compani within
credit suiss coverag univers base relationship compani
custom supplier competitor databas built research analyst
insight regard relationship credit suiss cover compani global
compani form core peer databas also includ relationship
stock coverag
inform see novemb peer report chain reaction suppli
charl martineau univers toronto compani mention price
